Meropenem pharmacokinetics in the newborn

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A5480" target="_blank" >RIV/00216208:11110/09:5480 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/09:5480 RIV/00216208:11150/09:10051673
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Meropenem pharmacokinetics in the newborn
Original language description
We studied meropenem in 23 pre-term (gestational age, 29 to 36 weeks) and 15 full-term (gestational age 37 to 42 weeks) neonates. Meropenem doses of 10, 20 and 40 mg/kg were administered as single doses (30-min intravenous infusion) on a random basis. Blood was obtained for determining the meropenem concentration nine times. Each child required other antimicrobials for proven/suspected bacterial infections. Samples were assayed obtained by employing the BigNPAG program. A Monte Carlo simulation was performed using the creatinine clearance nt organisms were to be treated (MIC of 4 to 8 mg/liter), the 40-mg/kg dose and a prolonged infusion was favored. Treating clinicians need to balance dose choices for optimizing target attainment against potential toxicity. These findings require validation in clinical circumstances.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FG - Paediatrics
OECD FORD branch
—

Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)